ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shuper, A
Right arrow Articles by Cohen, I J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shuper, A
Right arrow Articles by Cohen, I J
Arch Dis Child 1997;76:259-263 ( March )

Visual pathway glioma: an erratic tumour with therapeutic dilemmas

A Shuper,a G Horev,b L Kornreich,b S Michowiz,c R Weitz,d R Zaizov,a I J Cohena

a Schneider Children's Medical Center of Israel, Beilinson Medical Campus, Petah Tiqva, Sackler Faculty of Medicine, Tel Aviv University, Israel: Department of Pediatric Hematology-Oncology, b Department of Pediatric Imaging, c Department of Pediatric Neurosurgery, d Department of Pediatric Neurology

Correspondence to: Dr A Shuper, Department of Pediatric Hematology- Oncology, Schneider Children's Medical Center of Israel, Beilinson Medical Campus, Petah Tiqva 49202, Israel.

Accepted 12 September 1996

OBJECTIVE---Our experience in children with visual pathway glioma (VPG) was reviewed to delineate its clinical characteristics.
DESIGN---The charts and imaging studies of 21 children with VPG who were followed up in our centre during the last 12 years were reviewed and summarised.
RESULTS---VPG accounted for 13.1% of all brain tumours treated during this period. Sixty two per cent of the children with VPG had neurofibromatosis type 1 (NF-1). Among these, more than 60% were detected as part of routine work up. In some cases decreasing visual function preceded the appearance of the VPG on imaging studies. Tumour growth rate was markedly unpredictable. All treatment modalities employed led to tumour shrinkage and stabilisation for a variable period, but none was successful in totally eradicating the tumour. Complications were less severe after chemotherapy compared with radiotherapy. Three children died, none with NF-1, with a globular hypothalamic/chiasmatic tumour and accompanying electrolyte abnormalities.
CONCLUSIONS---NF-1 is a favourable prognostic marker for VPG. Whenever possible a period of observation is necessary before treatment is initiated, during which time tumour size and visual function should be closely followed up; an untoward change in either of these is an indication for the start of treatment, preferably chemotherapy first. The combination of a globular hypothalamic/chiasmatic glioma and electrolyte abnormalities in a child without NF-1 are related to a poor prognosis.


Key messages

  • The growth rate of VPG is unpredictable and erratic, especially in children with NF-1
  • Follow up needs both MRI of brain and visual function studies (funduscopic examination, visual fields and acuity, if possible)
  • Only symptomatic or growing tumours need treatment
  • Although both chemotherapy and radiotherapy should decrease or stabilise tumour growth, chemotherapy, with less side effects, should be used initially
  • Tumour progression is treated with chemotherapy, surgery, or radiotherapy
  • Patients without NF-1 who have globular tumours and electrolyte abnormalities may have a poor prognosis



Keywords: optic glioma; neurofibromatosis; chemotherapy; radiation therapy.

© 1997 by Archives of Disease in Childhood


This article has been cited by other articles:


Home page
 J Child NeurolHome page
E. Czyzyk, S. Jozwiak, M. Roszkowski, and R. A. Schwartz
Optic Pathway Gliomas in Children With and Without Neurofibromatosis 1
J Child Neurol, July 1, 2003; 18(7): 471 - 478.
[Abstract] [PDF]

Home page
 JCOHome page
M. Massimino, F. Spreafico, G. Cefalo, R. Riccardi, J. D. Tesoro-Tess, L. Gandola, D. Riva, A. Ruggiero, L. Valentini, E. Mazza, et al.
High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma
J. Clin. Oncol., October 15, 2002; 20(20): 4209 - 4216.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
J-F Chateil, C Soussotte, J-M Pedespan, M Brun, C Le Manh, and F Diard
MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis
Br. J. Radiol., January 1, 2001; 74(877): 24 - 31.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. R. Korf
Malignancy in Neurofibromatosis Type 1
Oncologist, December 1, 2000; 5(6): 477 - 485.
[Abstract] [Full Text]

Home page
 J Child NeurolHome page
G. Perilongo, P. Moras, C. Carollo, A. Battistella, M. Clementi, A. Laverda, and A. Murgia
Spontaneous Partial Regression of Low-Grade Glioma in Children With Neurofibromatosis-1: A Real Possibility
J Child Neurol, June 1, 1999; 14(6): 352 - 356.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1997 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health